JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CRINETICS PHARMACEUTICALS INC
I really do appreciate it. I think this is the last fireside chat for today. But by no means am I not excited to host the Vertex management team. I'm serious here. um uh suzy manisha really do appreciate um both of you making the trip over to london and uh i know that rushman might come in next year we're going to try to convince her so uh we'll see but um either way very very appreciative of your time i can tell you from a research perspective um vertex is one of um the names we're most excited about in large cap biotech and we do think 27 is setting up to be probably the most impactful year in terms of diversification away from cystic fibrosis, but then also a lot of strength in that franchise as well. So looking forward to the discussion. I'll hand it off to you for some intro remarks and we'll get started. Yeah. Thanks very much, Akash and the Jeffries team for having us. Thanks everyone in the room for sticking through to the bitter end here on Tuesday. And I think it is shaping up to be a really exciting year, but we've got a lot of exciting stuff still to do in 2026. Most notably, we are eagerly awaiting our November 30th PDUFA date for povitacicept in immunoglobulin A nephropathy. I'm excited for that, and I'm sure we'll go into more detail there. Also, by the end of the year, you'll have phase two proof of concept data for our DM1, our myotonic dystrophy type one compound. Then as you shift into 2027, early in the year in the first quarter, you'll have interim analysis phase three data from our amplitude study. This looks at anaxiplin and APOL1-mediated kidney disease patients. Really excited to see that. We had essentially a patient population expansion study read out earlier this year and amplified. So we're excited to see the full phase 3 interim analysis. If that is positive, then you could see us file for accelerated approval based upon that endpoint. Also in the first half of 2027, you will see the first results from a proof-of-concept study in povitacicep looking at myasthenia gravis. We fully enrolled that study. And by the middle of the year, you could see data from, we'd expect to see data, from two phase 3 studies looking at suzetrogene, which is our NAV1.8 inhibitor, and diabetic peripheral neuropathy. And these are the first phase threes for us in peripheral neuopathic pain or in chronic pain. Those are both set to complete enrollment. Both of those trials, by the end of this year, they're 12-week studies, so that puts us about mid-year for data there. And then there's more throughout the course of the year, but maybe I'll stop there and then talk about whatever you'd like. But I think as we continue to pursue additional launches this year in 26, We've talked about $500 million-plus in revenue from non-CF products. You add to that with the recent acquisition of Krenetics, and Palsan Fonofi will get us north of that because that's just Gernavix and Kazjevi. And we look for even more growth from non‑CF projects in 2027 while continuing to see a solid outlook for CF. Understood. You know, I was at ASMO, but my team was at ESN. Otherwise, I would have been there. Um, but I do think your team made an interesting argument on efficacy for Pova Tattersep. And I think one that maybe will age well, right? Because I think a lot of people say, okay, we have EGFR stabilization. They all look the same. But your team has been insistent when it comes to the consistency around geographies, hematuria, protein era getting onto certain levels. I think you're, you're really alluding that the puck may move. And so what doctors care about now versus what they may care about two, three years down the line might actually end up being different. Talk to me about your confidence that povitatercept is differentiated from an efficacy perspective beyond just proteinuria. And what are you hearing on the ground in terms of the evolving landscape and endpoints that doctors are going to increasingly focus on? Sure. Yeah. Thanks for the very good question. And we do think that we have potential best-in-class efficacy with POVI, and I'll go into detail, and we know we believe we have best- in-class patient administration or convenience factors, and hopefully we can talk about that too. But with respect to efficacy, recall that at our interim analysis, we had a 52% reduction in proteinuria, and that was just at 36 weeks, and competitors who saw a similar rate of reduction was actually out to 40 weeks. We know proteinuria continues to decline, so that was an earlier snap of it. We had greater than 80% reduction in resolution of hematuria. And we also had 42% of patients getting to Cadego guidelines. So I think how physicians are thinking about this, first off, POVI patients are otherwise healthy, typically younger, average age of diagnosis is in their mid 40s. And no patient, no physician wants blood or urine, a protein in their urine. So I think even small differences in proteinuria reduction compounded over time for a lifelong therapy could result in differences that are meaningful in terms of kidney function. And not necessarily do we think that stable is stable, but acting sooner, faster, having faster rates of decline could result In overall better clinical outcomes in terms of potentially staving off progression to dialysis, transplant, or even death. That'll be a long time to prove, but we're excited with the profile POVI being able to take that forward. And then, as I mentioned, on the patient administration aspect, we think a clear advantage there, given that we are, once every four weeks, dosing with an autoinjector with very low dose, 0.46 mL. We also have lower viscosity than peers, so it's less painful. And as I mentioned, at home with an auto-injector versus peers who are every four weeks or today with a pre-filled syringe and much higher dosages, or other peers are at weekly dosing. Now, you know, one of the things I've noticed, every other company I really talk to when it comes to IGAN and EGFR, one-year interim, one year interim, you actually, you really do stand out. There's not a single other company. to talk to who actually talks about the importance of two-year data, A, for global regulators, but B, as you think about building a data set where maybe it takes a little more time for the hematuria or the proteinuria, for Poet-Tattersup to differentiate on efficacy, right? So talk to me about data that you're going to generate long-term that would maybe support your view that any levels of proteinuria may actually lead to a worse outcome for patients, and how can you maybe generate that data internally? And talk to us about why you are such an outlier about looking for that two-year interim, I mean, that two year endpoint. And what do you think that gives you from an advantage perspective about the global market opportunity for these drugs? Yeah, that's really a key part of it is that there's only a pathway today currently for accelerated approval in the US. And I should also mention, we have filed for accelerated approval in the Kingdom of Saudi Arabia, where there's a pathway there. But otherwise, in Europe and in the Asian markets, it is a firm two-year EGFR endpoint. And while it's a significantly large, rare market opportunity in the U.S., we estimate 160,000 patients are today biopsy confirmed, diagnosed with IGAN, and we'd estimate a similar size population in Europe, that, you know, 330 sort of type of number pales in comparison to what we'd estimate as a million five or a million six globally. So we view Asia as the much larger patient opportunity. Just today, we saw the Chinese government approve two B-cell inhibitor agents for reimbursement in China. And I think that speaks to the need there. And we have partnered commercially with Ono Pharma in Japan and surrounding countries and with Zylab in China and surrounding companies, countries, excuse me. So I do think that that longer endpoint will begin to, we believe, bear out some of our theses about less proteinuria sooner is always a better thing, better hematuria resolution sooner is a better things because it shouldn't be there in your urine. And let's try and preserve as much nephron function as we can. I just thought of this question now, because you mentioned Zai and Ono you're partnered with. And there is this dynamic of the MFN of it all, right? And I hosted Pfizer earlier today. There was a panel, I think, yesterday, which really said, this is not a red wave, blue wave dynamic. This kind of a more equitable share of health care expenditure is a growing issue, and it's not going to go away, regardless of whether there's a Democrat or Republican in office in the United States. You have very uniquely partnered. You're working with external partners. When you're thinking about the ex-U.S. opportunity, can you talk a bit about how that gives you maybe more flexibility about preserving, you know, pricing in the United States, but then also really being able to meet some of these other countries where, you Know, from a economic perspective, they need to make sure it works for them. How does a partner actually help you do both? Right, I think that certainly, we chose to partner with Zion Ono more for the capabilities that they bring in a recognition that that was the most expedient and cost effective way for us to do that. And if there is more pricing flexibility in that type of construct, that would be sort of a nice byproduct. But we absolutely are thinking about povitacicept as sort of one of the first launches in this more MFN-aware environment, if you will. Recall for us, Gernavix is U.S. only. Casgevi is an in-hospital procedure and actually has very consistent pricing globally, sometimes even price a bit higher outside the U.S. And in cystic fibrosis, we don't go into the details. Many are under confidential agreement. But when you have your fifth medicine and continue to advance the therapy and launch new therapies, I think that puts you in a slightly better position than someone who launched, you know, 10, 15, 20 years ago and has just taken price increases in the U S. So we are absolutely thinking about POVI with that, with that construct. And I think that's probably another one of the advantages that we can bring to this market is our experience in cystic fibrosis in terms of negotiating reimbursement agreements in single payer systems and educating as to the value that our transformative therapies can bring. And so we're absolutely thinking about that as we consider the market opportunities in the countries where we'll enter. And again, I think it's back to younger patients, otherwise healthy, you know, dialysis or transplant are pretty tough alternatives and working through that. Okay. Understood. Now, I know there's kind of too many debates going into the POV-PJUFA. One is on, you know, monitoring requirements and the other one is really just from a manufacturing perspective. And, you know going into any event, I think companies will naturally qualify and tell you, you know, why things are okay. And I've noticed your team and Reshma very much has called their shot. You have a definitive view of what really the label will look like, the overall profile of Povitatorcept. And then I think, again, as much as you've been pushed and as annoying it can be, you guys have kind of expressed continued confidence on manufacturing. Can you explain a bit on, you know why your, your, Your team is so confident that you'd be able to deliver on both of those fronts going into the PDUFA? Sure. I think I'll try and address both the manufacturing talk or rumors as well as why we think we'll have a label that's consistent with the class, i.e. no monitoring of IGG. And frankly, it's data-driven. When you have a priority review, there is a strict six-month schedule. There's a cadence of events, inspections, et cetera. And what we have said consistently is that all of that has happened on the cadence that you would expect and that things remain on track and therefore we have high visibility and confidence in our November 30th PDUFA date. Similarly, with respect to why we think we'll have a label that will be consistent with the class is the only reason you would have monitoring for IgG is if you had reasons to believe there is increased infection risk with your therapy. And here, quite definitively, we have not seen that in the interim analysis. You had a very low rate of serious infections of 0.5%, and it was exactly the same in both the placebo and in the drug arm. So we just don't see the evidence for it. There's also, I think, pretty wide disparities in how the various trials have been constructed in terms of frequency of monitoring, even thresholds or definitions. So with lack of infection risk demonstrated in the data and based on our ongoing view of things, that's why we believe we'll have a label consistent with the class and again are on track for November 30th. Understood. Now, you know, it's I think sometimes when I talk to investors, it'S funny, you can say three good things, and then it'll be like, well, what did they not talk about? And so it's interesting sometimes with Propitatricep, you stress the global opportunity, but then the natural question becomes, oh, is the team less confident about the uptake in the U.S. market? And we've seen with both therapies that have currently launched really healthy and consistent patient ads, and we've seeing the class kind of expand. But there is this kind of debate of, well, what is the low-hanging fruit? And as you go through kind of the severe protein era patients, what's the moderate uptake look like? And then really what's long-term safety that patients want? And to be fair, we've also heard this sometimes with KOLs. So to be more focused, you're going to be launching without necessarily the EGFR long- term data, but you are going to be having the protein era reduction. Is your team confident that you can deliver the same uptake that you've seen with some of the existing therapies in the class? And really, what's your view of how the U.S. market opportunity plays out over time? Yeah, I think that we have been quite happy to see the initial uptake from the two competitors who have already launched and speaks to, again, that unmet need. these are otherwise patients who feel like they're kind of ticking time bombs waiting to see how fast their kidney decline progresses. So I think it's been great to see and points to what probably should be more of a TAM discussion, frankly, than a shared discussion, I would say. But I do think that we view our being third to market and not having EGFR data, we don't view those as hindrances per se. I think probably the most heavily proteinuric patients who'd been diagnosed a while ago with the first entrant, surely you'll see them pick that up. But even if you look at a better than expected launch, maybe 5,000 patients on drug already, that still leaves 155,000 in the United States for us to go after. And I think over time too, the opportunity for a switching market as well, although initial focus is naive. AndI do think you had mentioned it briefly, but I'd emphasize, again, the consistency of our results across all subgroups. And namely, the proteinuria decline is entirely consistent overall with the North American subgroup. And that's not the case with the two competitors. So in a U.S. launch, that'll be a key feature of our detailing messaging overall. We also can talk about a pipeline and a product where POVI is already in phase three for primary membranous nephropathy. And the rest of our pipeline, we mentioned inaxiplin and AMKD. We're also looking at autosomal dominant polycystic kidney disease. And we aim to have the largest share of voice. We haven't given the exact number, but we'll have the largest field force in the disease modifying agents. And then finally, it may be a smaller point, but 80% of our CF patients use our patient services programs. So this is where you can call, get a live person, help with getting on drug, navigating reimbursement, et cetera. And we'll replicate that model in renal. Understood. Good. And you brought a point that actually has come up with doctors. There is a bit of uncertainty on what is IgA. And sometimes you look at it and you say, actually, it's membranous nephropathy. How much of a competitive advantage would it be that you have an April BAF where, yes, you have IgA on the label, but B, you also have approvals in other kidney indications in terms of kind of capturing patients before, you know, a nephrologist figures out what they ultimately have, right? Do you feel like that's a key differentiator when you think about your clinical data package versus your peers? I guess maybe I would frame it as we think overall, having that mindshare of physicians knowing, nephrologists knowing that we have four disease-modifying therapies, this renal renaissance where they previously have really just had repurposed cardiovascular medicines. If you recall, our IGAN study was the fastest to enroll. And I think that was because we didn't just show up and say, here, we have POVI. They knew us from our AMKD enrollment. They know us from other activities as well. So I'd say it's probably a combination of the two, but definitely seeking to have significant mindshare with physicians and translate that into faster enrollments, faster uptake of commercialized products, et cetera. Now, maybe switching to anoxiplin, and who knows, maybe early next year, we could have an interim. I mean, I don't think people understand how quick Amplitude could be reading out. There's another example of where I feel like your team and Reshma has been very, let's say, marked with her language and not qualified going into an event. Again, you would have every excuse to say, look at Parasol, look the underserved population. We have precedents in FSGS where you can use ProNira as a basis for an approval. but i haven't heard you say that i haven t heard your team say that and your consistent messaging as fda is looking at egfr and that's what we're looking at as well why the confidence on being able to hit on egfr at this interim i know it's over 200 patients and can you comment a bit about what you've seen in terms of long-term duration with your phase two data sets as you follow these patients over an extended period of time. Yeah. So on the first question, so what we know about APOL1-mediated kidney disease is you need two APOL01 variants, right? And if you have those variants, your disease progression, your decline in kidney function is likely to be about 50% faster than those who don't have the variants. So you're losing six to seven mLs per minute per year versus more like, say, four in people who don't have the two APOL1 variants. We also know that our drug, Anaxoplin, is inhibiting about 98% plus of APOL-1. And then finally, I think I'd point you to the two Phase II data sets that we have, where in our initial Phase II study, we saw at 13 weeks a 47.6% reduction in proteinuria. And so I think consistently the data sets continue to come in that that is correlated with what we need to achieve here would be it's a separation of the curves of EGFR slope, onoxiplin versus placebo on top of standard of care. So given how rapidly these patients decline, how well we know we're inhibiting APOA1, and what we've seen in terms of proteinuria reduction, and even with IGAN seeing how that does translate to relative stabilization, that's why we are optimistic for the interim analysis. And definitively, our conversations with FDA have been, we're measuring both EGFR slope as well as proteinuria, but we need to hit on EGVR slope to file for the accelerated approval. We also recently saw amplified results in the more modest proteinuria group. So that was 0.3 to 0.7 grams per gram versus amplitude. The phase three study is 0.6 grams per kilogram. 0.7 or above. Even there, we saw at 13 weeks, right, a 44% reduction in proteinuria. So very consistent, even with less dynamic range in terms of the reduction of proteinuria, so that is all what gives us confidence, but we need to see the data, and as you said, we will see it early in 2027. Understood. Now, on the Q3 call, I think Resha made some very interesting and quite specific comments about how she expected EGFR in the placebo arm to really perform. And your team actually has presented natural history data on this as well. And I think one of the things that maybe most investors know, diabetic might be a little trickier than FSGS. But what I don't think people appreciate is that there's also a lot of variation in terms of rates of decline, even within specific genotypes in APO1 itself. So here's where it gets kind of interesting. The confidence in which Reshma said what she expected is also backed by, I think, some of your natural history publications. But then there's this interesting dynamic of you have unique visibility on, even if they're not diabetic, what variants of APO2 is in amplitude. Um, and some have even a 17 point decline. I mean, there, there's some really, really rapid progressors there. So let's put it this way. What did you learn from your natural history publications in terms of the right types of patients to enroll if you're focused on hitting on EGFR? And can you give us a hint of what's been the breakdown in amplitude for the 200 patients that are in that interim analyses? No, I cannot on the second part of your question. And I will say that there has been a huge initiative on our part to work with partners and to get genotyping studies up and running and underway, and then to enroll patients in the study. And this was a very global study as well. It's taken us a very long time to enroll and are quite pleased that we've been able to conclude that. But I think to us, and the amplified results validated this as well, there had been a school of thought that it really was FSGS that mattered. And we definitively view that as not what matters. That's just a histological diagnosis of a scarring pattern. What matters is two APOL1 variants. And I think that our view is that it is actually, while there may be variations, that is the crux of the matter and will take all comers. In fact, we would also take, if you have FSTS, if you've had the biopsy diagnosis, you're welcome in the study. If you haven't, you'RE welcome in the study. It really just comes down to when we genotype you, do you have those two variants? So perhaps more to come on ranges within that. But again, our natural history or the literature would suggest that placebo arms should decline something in that six, seven mils per minute per year. Understood. said. And as we think about the market opportunity here, I think people have grown, like we get eigen, right? Like this is disease modifying. No one wants to get on dialysis. But on AMTD, I think, I don't know if people understand what the long-term TAM could be, but there's also unique challenges. You're talking about an underserved community, mostly African-American population, and it's going to take time to really educate and actually, you know, get patients on therapy. So when your team thinks about the TAM longer term, how does that compare to, let's say, the IGAN opportunity for pubitatricep? But then number two, what will it take to really commercialize a drug in this market? And how should we think about uptake over time? Yeah. So I think unlike IGAN, where these patients are already biopsy confirmed, diagnosed, and waiting, oftentimes with an AMKD patient, they've not been genotyped. They just know that they have chronic kidney disease, and they probably know that they're heavily proteinuric and losing function rapidly. I think increasingly physicians are aware that they should be genotyping both their Black and actually Hispanic patients to see if they have the two APO1 variants. And we have been doing a lot of education work. Again, I mentioned the genotyming studies. We also partnered with Alonzo Mourning, who had the disease, an NBA Hall of Famer. He's been tireless in his efforts in reaching out to community groups and church groups, et cetera. And I think the intent here is likely to launch with a companion diagnostic and build this as the first precision genetic medicine for kidney disease. And as our physician mentioned at our ASN event, right there, the prevalence among black families is well in excess of their percentage of the population. There's not a black family you can meet that doesn't know someone in their family with kidney disease. So I think increasing awareness. And once you have a disease-modifying therapy, I think it's a little bit of our hope is build it, you will come. But we do think, and we don't give market size, but the epidemiology estimate we have is similar in size to POVI, and that's the 150,000 that we give in the U.S. for those with modest to severe proteinuria, 2A1 alleles, and no comorbidities. If you add comorbidities like type 2 diabetes to it, you get another 100,000 patient opportunity. Understood. Last question, because I don't think there is another one, so we can go a little over. Chronetics. And this was a deal where I don' t know if everyone expected it, because again, you had a bunch of kidney readouts. So it wasn' t like you were a company that was lacking in terms of impactful catalysts for 27, but it did feel like Rushman really wanted to be a on the offensive but b it was i know more than you i've been able to diligence this asset um and um i do think that's something i'd love for you to talk a bit more about right um i i think for the cah drug really strong a4 reductions the investor debate was always around liver toxicity what have you learned when you did the initial diligence on the deal what have you learned as you've gotten more longer term follow-up data and also maybe more patience that would help investors feel comfortable about the safety profile for that drug for CH? Sure. So I'll start with your question just around the transaction and why we did it and when we did It. So we had been looking at Krenetic since earlier this year, since January or so. We really liked what we saw. It fit perfectly with our strategy of severe disease with well-known, well-understood causal biology, specialty markets. So a perfect fit. And as we continued our diligence, we began to think this company might be undervalued, and we wanted to move quickly and snap it up before others sort of cottoned on to that. In terms of safety in the CAH study, so there was only one liver event in the phase two that could not be ruled out definitively as related to atumelanin, but there are no cases of Heye's law, and it was found toward the very end of the study. So the patient went off drug and it resolved. I will add that phase two is ongoing in an open label extension, and we have not seen any additional liver events in those data. And we'll present the fuller data set at a medical meeting that's in 27. Understood. And maybe just lastly, just any comments about enrollment for the ongoing phase three and timing there? Yeah. So we expect to complete enrollment in Q1 of 2027, and then it's 32 weeks of dosing. So we could be looking at late 27 or early 28 for a data readout. I can't help but think if we think about the quote unquote liver event that happened in phase two, it was around 12 weeks. By the time we get into mid next year, if there was, I mean, it does seem like as more time goes on, we, you know, the street as a whole should feel a little more comfortable about, um, the safety profile is, would you agree with that? Yeah, I think as with any ongoing study, you know, with an IDMC monitoring it, et cetera, if there's something that's a deal breaker or alarming that, you Know, we would find out about it. So, um. And again, we look forward to sharing the phase two open label extension data. Amazing. Thank you so much. I really do appreciate it. Wonderful discussion. Thank you. Thank you. Take care.
- Company
- CRINETICS PHARMACEUTICALS INC
- Keywords
- CRINETICS PHARMACEUTICALS INC